Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 12/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664178 | 0.91 | PTAFR (0.48) | PTAFROPRK1PDE4DTBXAS1 | |
| SCHEMBL5663501 | 0.89 | PTAFR (0.38) | PTAFRHPGDHSD17B10OPRK1PDE4D | |
| SCHEMBL5666605 | 0.88 | PTAFR (0.46) | PTAFROPRK1PDE4DTBXAS1 | |
| SCHEMBL5665916 | 0.88 | PTAFR (0.36) | PTAFRUSP2ALDH1A1HPGDALOX15 | |
| SCHEMBL5664204 | 0.87 | PTAFR (0.45) | PTAFROPRK1PDE4DTBXAS1 | |
| SCHEMBL5663624 | 0.87 | PTAFR (0.45) | PTAFROPRK1PDE4DTBXAS1 | |
| SCHEMBL5664536 | 0.85 | OPRK1 (0.45) | PTAFROPRK1PDE4D | |
| SCHEMBL5663627 | 0.82 | OPRK1 (0.48) | PTAFROPRK1PDE4DTBXAS1 | |
| SCHEMBL5666050 | 0.81 | BRD4 (0.35) | PTAFRHPGDOPRK1 | |
| SCHEMBL5663268 | 0.80 | BRD4 (0.34) | PTAFRHPGDOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | claimed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | claimed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | PTAFR 3904/4885USP2 1231/4885ALDH1A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.